SENZUMODERN REBIRTHMy account CJC-1295
Also known as CJC-1295 with DAC · cjcipa · DAC:GRF
Early trials demonstrated prolonged increases in growth hormone and IGF-1. They did not establish clinical benefit for fat loss, muscle gain, recovery, sleep, or longevity.
- Evidence maturity
- Early signal
- Regulatory status
- Not FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 2
This profile does not recommend a compound, dose, supplier, or treatment plan. Discuss personal decisions with a qualified clinician who knows your history.
Summary
An unapproved long-acting GHRH analog studied in small healthy-volunteer trials.
What is CJC-1295 being studied for?
Growth hormone and IGF-1 pharmacology
How is it thought to work?
A GHRH-receptor agonist whose drug-affinity-complex design prolongs exposure and GH/IGF-1 stimulation.
Recorded outcomes
3 graded outcomes and 2 sources for CJC-1295.
The graded outcome table, how each grade was decided, the regulatory detail, and every source with its link and identifier open with a free account. No payment details required.
Update history
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.